^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

vilastobart (XTX101)

i
Other names: XTX101, XTX 101, XTX-101
Company:
Xilio Therap
Drug class:
CTLA4 inhibitor
4ms
Enrollment change • Combination therapy • Metastases
|
Tecentriq (atezolizumab) • vilastobart (XTX101)
11ms
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer. (PubMed, J Immunother Cancer)
These data demonstrate that XTX101 retains the full potency of an Fc-enhanced CTLA-4 antagonist within the TME while minimizing the activity in non-tumor tissue, supporting the further evaluation of XTX101 in clinical studies.
PK/PD data • Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8)
|
Yervoy (ipilimumab) • vilastobart (XTX101)